239 related articles for article (PubMed ID: 18923884)
1. Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis.
Lindsay R; Miller P; Pohl G; Glass EV; Chen P; Krege JH
Osteoporos Int; 2009 Jun; 20(6):943-8. PubMed ID: 18923884
[TBL] [Abstract][Full Text] [Related]
2. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.
Prince R; Sipos A; Hossain A; Syversen U; Ish-Shalom S; Marcinowska E; Halse J; Lindsay R; Dalsky GP; Mitlak BH
J Bone Miner Res; 2005 Sep; 20(9):1507-13. PubMed ID: 16059622
[TBL] [Abstract][Full Text] [Related]
3. Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index.
Genant HK; Siris E; Crans GG; Desaiah D; Krege JH
Bone; 2005 Aug; 37(2):170-4. PubMed ID: 15961357
[TBL] [Abstract][Full Text] [Related]
4. Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy.
Ste-Marie LG; Schwartz SL; Hossain A; Desaiah D; Gaich GA
J Bone Miner Res; 2006 Feb; 21(2):283-91. PubMed ID: 16418784
[TBL] [Abstract][Full Text] [Related]
5. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women.
Uusi-Rasi K; Semanick LM; Zanchetta JR; Bogado CE; Eriksen EF; Sato M; Beck TJ
Bone; 2005 Jun; 36(6):948-58. PubMed ID: 15878318
[TBL] [Abstract][Full Text] [Related]
6. Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis.
Krege JH; Wan X
Bone; 2012 Jan; 50(1):161-4. PubMed ID: 22036910
[TBL] [Abstract][Full Text] [Related]
7. [Therapeutic agents for disorders of bone and calcium metabolism--Teriparatide, parathyroid hormone (1-34) as a daily subcutaneous injection].
Hashimoto Y; Wakayama N; Miyauchi A
Clin Calcium; 2007 Jan; 17(1):48-55. PubMed ID: 17211093
[TBL] [Abstract][Full Text] [Related]
8. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
Neer RM; Arnaud CD; Zanchetta JR; Prince R; Gaich GA; Reginster JY; Hodsman AB; Eriksen EF; Ish-Shalom S; Genant HK; Wang O; Mitlak BH
N Engl J Med; 2001 May; 344(19):1434-41. PubMed ID: 11346808
[TBL] [Abstract][Full Text] [Related]
9. Reduced risk of back pain following teriparatide treatment: a meta-analysis.
Nevitt MC; Chen P; Dore RK; Reginster JY; Kiel DP; Zanchetta JR; Glass EV; Krege JH
Osteoporos Int; 2006 Feb; 17(2):273-80. PubMed ID: 16142502
[TBL] [Abstract][Full Text] [Related]
10. Back pain during different sequential treatment regimens of teriparatide: results from EUROFORS.
Lyritis G; Marin F; Barker C; Pfeifer M; Farrerons J; Brixen K; del Pino J; Keen R; Nickelsen TN;
Curr Med Res Opin; 2010 Aug; 26(8):1799-807. PubMed ID: 20482322
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
[TBL] [Abstract][Full Text] [Related]
12. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
Adachi JD; Hanley DA; Lorraine JK; Yu M
Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
[TBL] [Abstract][Full Text] [Related]
13. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment.
Miller PD; Schwartz EN; Chen P; Misurski DA; Krege JH
Osteoporos Int; 2007 Jan; 18(1):59-68. PubMed ID: 17013567
[TBL] [Abstract][Full Text] [Related]
14. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis.
Marcus R; Wang O; Satterwhite J; Mitlak B
J Bone Miner Res; 2003 Jan; 18(1):18-23. PubMed ID: 12510801
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of teriparatide in postmenopausal women with osteoporosis and glucocorticoid use: 3-year results from the EFOS study.
Karras D; Stoykov I; Lems WF; Langdahl BL; Ljunggren Ö; Barrett A; Walsh JB; Fahrleitner-Pammer A; Rajzbaum G; Jakob F; Marin F
J Rheumatol; 2012 Mar; 39(3):600-9. PubMed ID: 22247365
[TBL] [Abstract][Full Text] [Related]
16. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.
Kendler DL; Marin F; Zerbini CAF; Russo LA; Greenspan SL; Zikan V; Bagur A; Malouf-Sierra J; Lakatos P; Fahrleitner-Pammer A; Lespessailles E; Minisola S; Body JJ; Geusens P; Möricke R; López-Romero P
Lancet; 2018 Jan; 391(10117):230-240. PubMed ID: 29129436
[TBL] [Abstract][Full Text] [Related]
17. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
18. Teriparatide and raloxifene reduce the risk of new adjacent vertebral fractures in postmenopausal women with osteoporosis. Results from two randomized controlled trials.
Bouxsein ML; Chen P; Glass EV; Kallmes DF; Delmas PD; Mitlak BH
J Bone Joint Surg Am; 2009 Jun; 91(6):1329-38. PubMed ID: 19487509
[TBL] [Abstract][Full Text] [Related]
19. The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis.
Genant HK; Halse J; Briney WG; Xie L; Glass EV; Krege JH
Curr Med Res Opin; 2005 Jul; 21(7):1027-34. PubMed ID: 16004669
[TBL] [Abstract][Full Text] [Related]
20. Teriparatide: new preparation. Osteoporosis: less well evaluated than alendronic acid.
Prescrire Int; 2005 Feb; 14(75):5-9. PubMed ID: 15747448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
